Announcement

Collapse
No announcement yet.

xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)

    xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)

  • #2
    Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

    This compassionate use program is for Glioblastoma (and any other cancer) patients who have mutations in the MAPK pathway including these mutations: KRAS, NRAS, HRAS, BRAF, MEK, and ERK, Take a look at your pathoilogy report and see if any of those mutations are present. If they are, ask your doctor about this program.

    Disclaimer: I own stock in xCures and work as a paid consultant for them.

    Comment

    Working...
    X